CME to launch European HICP inflation futures

The Chicago Mercantile Exchange is set to launch a European inflation futures contract based on the eurozone harmonised index of consumer prices (HICP), excluding tobacco, an annual inflation measure published by Eurostat, on September 19. The contracts will trade on the CME Globex trading platform between 8am and 4pm UK time.

The CME may have responded to criticism of its US consumer price index futures contract, which has failed to get off the ground since its launch in February 2004. The European contract will be based on a notional value of €1 million for 12 months and will be quoted as 100 minus the annual inflation rate in the 12-month period preceding the contract month. Inflation traders have criticised the US contract because the quarterly CPI on which it is based introduced too much seasonal volatility, which pushed dealers away from market-making.

“The contract’s monthly expiration will generate interest from inflation swap desks at major banks as well as asset managers and active traders like hedge funds looking for trading opportunities,” said Robin Ross, managing director of CME interest rate products. “An active short-term inflation hedge will allow dealers to free-up their capital to create more structured products of medium- and longer-term tenures, thus contributing to the further growth of the European inflation derivatives market.”

Whereas Barclays Capital was the only market-maker for the US contract, the CME anticipates it will have several market-makers when the HICP futures are launched. The exchange is offering a six-month fee waiver for Globex and clearing fees to all market participants at launch.

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Most read articles loading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here